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Abstract
Context: Growth hormone (GH) treatment has a generally good safety profile; however,
concerns about increased mortality risk in adulthood have been raised.
Objective: This work aims to assess the long-term safety of GH treatment in clinical
practice.
Methods: Data were collected from 676 clinics participating in 2 multicenter longitudinal
observational studies: the NordiNet International Outcome Study (2006-2016, Europe)
and ANSWER Program (2002-2016, USA). Pediatric patients treated with GH were
classified into 3 risk groups based on diagnosis. Intervention consisted of daily GH
treatment, and main outcome measures included incidence rates (events/1000 patientyears) of adverse drug reactions (ADRs), serious adverse events (SAEs), and serious
ADRs, and their relationship to GH dose.
Results: The combined studies comprised 37 702 patients (68.4% in low-risk, 27.5% in
intermediate-risk, and 4.1% in high-risk groups) and 130 476 patient-years of exposure.
The low-risk group included children born small for gestational age (SGA; 20.7%) and
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Treatment with recombinant human growth hormone
(GH) is used widely in children with growth failure to improve linear growth and with the aim of achieving normal
adult height. Treatment with GH has been approved for
a variety of indications, including GH deficiency (GHD),
short stature in children born small for gestational age
(SGA), chronic kidney disease, Turner syndrome, Noonan
syndrome, and Prader-Willi syndrome. In the United States,
it has also been approved for idiopathic short stature.
Long-term effectiveness and safety of GH treatment
in clinical practice has been demonstrated in several longitudinal observational studies (2-11). However, concerns
were raised following the preliminary French retrospective
study “Safety and Appropriateness of Growth hormone
treatments in Europe” (SAGhE) regarding an increase in
adult mortality following GH treatment in childhood,
in patients categorized a priori into a low-mortality risk
group (n = 6928) (12). The risk appeared the highest in patients who received GH doses greater than 50 µg/kg/day,
for whom the incidence of bone tumors and cerebral hemorrhage increased (12, 13). In another preliminary SAGhE
study from Belgium, the Netherlands, and Sweden, in the
low-risk group (n = 2543) the majority of deaths (76%;
16/21) were caused by accidents and suicides, and patients did not die of cardiovascular disease or cancer (14).
Lastly, in a recent report from the full SAGhE consortium
(Belgium, France, Germany, Italy, the Netherlands, Sweden,
Switzerland, and the United Kingdom), with up to 25 years
of follow-up and 24 232 patients categorized into 3 risk
groups, it was reported that, while some cause-specific
mortality from circulatory and hematological diseases was
increased in all groups, the mortality was not associated
with GH doses in any risk group (15).
We address the long-term safety of GH treatment in
pediatric patients by evaluating data from 2 complementary noninterventional studies with a common design:
the NordiNet International Outcome Study (IOS) and the

American Norditropin Studies: Web-Enabled Research
(ANSWER) Program. Interim results from NordiNet IOS
have previously been published, after evaluating safety data
from 13 834 patients categorized into groups by mortality
risk and stratified by average GH dose (16). No safety signals were observed, and no association between GH dose
and the incidence of adverse events (AEs) was found (16).
In this paper, we report a combined analysis from the
NordiNet IOS and the ANSWER Program, evaluating
the entire safety data set from more than 37 000 patients
from 23 countries, with up to 10 years of follow-up (17).
We evaluated the frequency and incidence rates of serious
(SAEs) and/or treatment-related AEs reported during GH
treatment in pediatric patients enrolled in the NordiNet
IOS and ANSWER Program, who were classified into 3 risk
groups based on their diagnosis as per the SAGhE cohort
study categorization. We also investigated the effect of GH
dose on the incidence rates of AEs and report details on
events of special medical interest.

Materials and Methods
Study Design and Ethics
The NordiNet IOS (NCT00960128) and ANSWER
Program (NCT01009905) were noninterventional,
multicenter registry studies monitoring the long-term
outcomes of GH treatment (with Norditropin; Novo
Nordisk A/S) in children and adults, in real-world clinical practice. The NordiNet IOS was ongoing between
April 2006 and December 2016 and involved 469 clinics
in 22 countries throughout Europe and the Middle East;
the ANSWER Program took place from June 2002 to
September 2016 in 207 clinics in the United States. The
designs of both studies have previously been reported in
detail (17, 18).
The 2 studies were complementary, with similar aims
and using the same data management electronic platform.
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non-SGA children (eg, with GH deficiency; 79.3%). Average GH dose up to the first adverse
event (AE) decreased with increasing risk category. Patients without AEs received higher
average GH doses than patients with more than one AE across all groups. A significant
inverse relationship with GH dose was shown for ADR and SAE incidence rates in the
low-risk group (P = .003 and P = .001, respectively) and the non-SGA subgroup (both
P = .002), and for SAEs in the intermediate- and high-risk groups (P = .002 and P = .05,
respectively).
Conclusions: We observed no indication of increased mortality risk nor AE incidence
related to GH dose in any risk group. A short visual summary of our work is available (1).
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Minor differences in study design have been described
elsewhere (17). Both studies were conducted with approval from relevant ethics committees, written consent
from patients, and pseudonymization of all data in accordance with the Declaration of Helsinki, Guidelines for
Good Pharmacoepidemiology Practices, and regulatory
requirements.

The patient population analyzed in this study included
children with GHD, Turner syndrome, Noonan syndrome,
Prader-Willi syndrome, idiopathic short stature, or those
born SGA, who were treated with GH as prescribed by the
treating physician. Patients were classified into 1 of 3 main
risk categories based on clinical diagnosis at the start of GH
treatment and associated risk for long-term mortality (irrespective of GH treatment), as described previously (12, 15)
and summarized in Table 1. If a patient had several diagnoses, categorization was based on the diagnosis belonging
to the highest risk group. Patient classification into risk
groups was carried out by the study sponsor and reviewed
by 2 pediatric endocrinologists (authors L.S. and J.R.).

Safety Evaluation
Safety was evaluated on the basis of AEs reported by the
treating physicians. Events reported prior to the GH treatment start were excluded from the analysis, as well as AEs
reported after age 20 years.
Events evaluated in this analysis included (i) SAEs, (ii)
AEs considered possibly/probably related to GH treatment,
either by the reporting physician or the study sponsor
(adverse drug reactions; ADRs), and (iii) serious ADRs

Statistical Analysis
All code for statistical analyses was written using the SAS
9.4 software. Baseline and exposure data were summarized using descriptive statistics. The overall duration of
GH treatment was calculated for each patient in patientyears of exposure, from the date of first treatment to the

Table 1. Diagnoses at start of growth hormone treatment used for classification of patients into risk groups
1. Low-risk group

2. Intermediate-risk group

3. High-risk group

A. Non-SGA subgroup

Multiple pituitary hormone
deficiency
Severe cerebral malformation
Short stature and severe
extracerebral malformation
Chromosomal anomalies, including Turner syndrome
Clinically defined syndromes
Severe chronic pediatric disease
Long-term steroid use in chronic
inflammatory disease
Benign pituitary tumors
Cushing disease

All malignancies
Langerhans cell histiocytosis
After bone marrow or solid transplantation
Chronic renal failure
Syndromes with known increased risk for malignancies (eg, Bloom,
Fanconi, Down, and chromosomal breakage syndromes)
Previously treated for cancer

Isolated GHD
Idiopathic short stature
Isolated GHD with a minor craniofacial malformation (eg, cleft lip)

B. SGA subgroup
Short stature in children born SGA

Abbreviations: GHD, growth hormone deficiency; SGA, small for gestational age.

Craniopharyngioma
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Patient Population

(SADRs). Nonserious and non–GH-related AEs were not
included in this analysis, in line with the publication of
interim data from the NordiNet IOS (16). AEs were considered serious if they resulted in death, a life-threatening
experience, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity,
or were associated with a congenital anomaly/birth defect,
or important medical events.
An overlap exists between the reported types of AEs.
SADRs are a subset of SAEs that are considered related to
GH treatment. Similarly, SADRs form a subgroup of ADRs,
as ADRs include all nonserious and serious AEs related to
GH treatment. Therefore, the total number of events reported in this analysis is the sum of SAEs and ADRs minus
the number of SADRs.
All ADRs, SAEs, and SADRs were coded with the Medical
Dictionary for Regulatory Activities terms (version 14.0)
using system organ class (SOC) terminology. Incidence of
events by SOC is reported for preferred-term events that occurred more than 10 times. Exceptions reported in more detail are (i) events of special interest, including neoplasms and
cardiovascular events, and (ii) targeted AEs that occurred in
previous studies, such as slipped capital femoral epiphysis
(SCFE), increased intracranial pressure (ICP; diagnosed by
lumbar puncture, computed tomography, or magnetic resonance imaging), edema, and headache (6, 8, 19-21).

57.4/42.6
SGA

Abbreviations: AE, adverse event; CDC, US Centers for Disease Control and Prevention; GH, growth hormone; IGF-1, insulin-like growth factor-1; NA, not available; SDS, SD score; SGA, small for gestational age.

3.7 (2.9)
–0.9 (0.9)
8.2 (3.5)

NA

–2.7 (0.9)

–0.7 (1.6)

3.0 (2.5)
–0.6 (1.0)
72.7/27.3

20 448 (79.3% of
low-risk group)
5342 (20.7% of
low-risk group)

10.6 (3.7)

NA

–2.2 (1.0)

–1.3 (1.7)

3.7 (2.8)
3.5 (2.8)
–0.2 (1.0)
–0.6 (1.0)
59.5/40.5
63.3/36.7
1543 (4.1)
37 702 (100.0)

10.3 (3.8)
9.7 (4.0)

1081 (70.3)
27 740 (73.8)

–2.0 (1.4)
–2.3 (1.1)

–1.9 (2.1)
–1.2 (1.8)

3.2 (2.6)
4.2 (3.2)
–0.7 (1.0)
–0.4 (1.0)
69.5/30.5
48.5/51.5
25 790 (68.4)
10 369 (27.5)

10.1 (3.8)
8.4 (4.5)

19 562 (76.0)
7097 (68.6)

–2.3 (1.0)
–2.5 (1.3)

–1.2 (1.7)
–1.3 (1.9)

Duration of GH
treatment, y
IGF-1 SDS
at baseline
Height SDS
at baseline
GH-naive at study
inclusion, n (%)
Age at GH treatment start, y
Sex, male/
female, %

Low risk
Intermediate
risk
High risk
All
Low-risk subgroups
Non-SGA

In total, 37 702 patients received GH treatment during
130 476 patient-years of exposure. There were 9873
(26.2%) previously GH treated (nonnaive) children and
27 740 (73.8%) GH-naive children (Table 2). Of the 89
remaining patients with an undetermined history of GH
treatment, only 1 had reported an AE.
The majority of patients (25 790; 68.4%) were classified into the low-risk group, while 10 369 (27.5%) and

Patients in group,
n (% of total)

Patient Characteristics

Risk group

Results
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end of the treatment or the patient’s last visit. The average
GH dose up to the onset of the first AE was used instead
of the average GH dose throughout the whole treatment
period, for a more accurate analysis of the relationship
between AEs and the GH dose. However, for a GH dose
comparison between patient groups that did or did not experience AEs, the average GH dose throughout the treatment period was used for patients who did not experience
any AEs. This comparison was carried out using the t test,
and the Satterthwaite approximation was used in the case
of inequality of variances (22). Statistically significant differences in all analyses were defined as a P value lower
than .05.
In each risk group and low-risk subgroup, patients were
stratified into 3 GH dose groups based on their average GH
dose up to the first AE: 0 to 30, greater than 30 to 40, and
greater than 40 μg/kg/day. Unlike the previous analysis of
the NordiNet IOS (16), patients in dose groups 0 to 20 and
greater than 20 to 30 μg/kg/day were pooled together because of the relatively low numbers of patients treated with
a GH dose below 20 μg/kg/day.
Incidence rates of ADRs, SAEs, and SADRs were calculated as the number of events within the study period
per 1000 patient-years of exposure for each risk group
and each GH dose group. The incidence rates were compared among the risk groups and between the low-risk
subgroups by Poisson regression (log-linear model). The
relationship between average GH dose up to the first AE
and the occurrence of ADRs, SAEs, and SADRs was analyzed using Poisson regression (log-linear model) with the
mean GH dose up to the first AE as a continuous explanatory variable.
The incidence of AEs by the duration of follow-up was
studied by calculating the proportion of patients experiencing a given type of AE, in a given year, out of all patients exposed that year for the first 5 years of follow-up.
The correlation between AE incidence and duration of GH
treatment was analyzed with the Spearman rank-order
correlation.

Target height
SDS (CDC)

The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 6

Table 2. Baseline characteristics by risk group
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Growth Hormone Dose up to First Adverse Event
Average and cumulative absolute GH doses and duration of GH treatment up to the onset of the first AE are
summarized for each risk group in Table 3. The average
GH dose prior to the first AE was significantly higher in
the low-risk group than in the intermediate-risk group
(P = .013), and the dose both in the low- and intermediaterisk groups was significantly higher compared with that in
the high-risk group (P < .001 for both). The average GH
dose prior to the first AE did not differ significantly between the low-risk subgroups. Duration of GH treatment
up to the first AE onset was longer in the intermediaterisk group (2.9 years) and similar in the low- and high-risk
groups (2.4-2.5 years). Cumulative absolute dose prior to
the first AE was higher in the low- and intermediate-risk
groups (579-584 mg) compared with the high-risk group
(543 mg) (see Table 3).
In the low-risk subgroups, GH dosing between the nonSGA and SGA patients appeared similar; however, nonSGA patients received a higher cumulative absolute GH
dose compared with the SGA group.
Almost half of all patients (49.8%) received an average
GH dose of more than 40 μg/kg/day up to the first AE. The
largest proportion of patients receiving such a dose was in
the low-risk group (54.3% of patients), particularly in the

non-SGA subgroup (57.4% of the low-risk group). Only
28.6% of patients in the high-risk group received GH doses
of more than 40 μg/kg/day (Table 4). The proportion of patients receiving a GH dose of 30 to 40 μg/kg/day before the
first AE onset was similar across all risk groups (28.7%31.5%); however, this dose range was more prevalent in
the SGA subgroup (45.5%) compared with the non-SGA
subgroup (27.8% of the low-risk group) (see Table 4).
The average GH dose in patients who did not experience any AEs, compared with patients who experienced at
least one AE, appeared higher in all 3 risk groups (Fig. 1A)
and in the low-risk subgroups (Fig. 1B). This difference was
significant in the low-risk group (P < .001), intermediaterisk group (P = .007) and in the non-SGA low-risk subgroup (P < .001).

Frequency and Incidence Rates of Adverse Events
During the 2 studies, 849 patients (2.3%) experienced
1242 AEs (Table 5). Among the risk groups, proportionally
more patients experienced AEs in the high-risk group (107;
6.9% of the group) and the intermediate-risk group (361;
3.5%), compared with the low-risk group (381; 1.5%).
Within the low-risk group, a slightly higher proportion of
the SGA patients experienced AEs (93; 1.7%) compared
with the non-SGA patients (288; 1.4%). Among the types
of AEs, ADRs were most prevalent in the low-risk group
(particularly in the non-SGA subgroup, in which they represented 81.4% of events). SAEs occurred most frequently
in the high-risk group (70% of events). SADRs comprised
190 (15.3%) of all events and occurred at a similar rate
across all groups.
Incidence rates (events per 1000 patient-years within the
study period) were the lowest in the low-risk group (4.7
for ADRs, 2.3 for SAEs, and 0.9 for SADRs) and increased
with each higher risk category (7.2 for ADRs, 8.1 for SAEs,
and 2.1 for SADRs in the intermediate-risk group, and
13.9 for ADRs, 20.5 for SAEs, and 5.0 for SADRs in the
high-risk group). These differences were statistically significant among all risk groups for all 3 event types (P < .0001
for all comparisons; Fig. 2A). For the low-risk subgroups,
the incidence rate of ADRs was significantly higher in the
non-SGA patients (P = .05), whereas the incidence rate
of SAEs was significantly higher in the SGA subgroup
(P = 0.001) (Fig. 3A). The incidence rate of SADRs was not
significantly different between these subgroups (P = .472).
The incidence rates of ADRs, SAEs, and SADRs were
also compared in subgroups of patients stratified into GH
dose categories, based on average GH dose prior to the first
AE onset. The patient distribution into GH dose groups
is summarized in Table 4. When evaluating the mean GH
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1543 (4.1%) were classified into the intermediate-risk and
high-risk groups, respectively. Within the low-risk group,
20 488 patients were classified as non-SGA and 5342 as
SGA (79.3% and 20.7% of the low-risk group, respectively).
General baseline characteristics of the patients have
been published elsewhere (17). Baseline characteristics
of patients grouped by risk category are summarized in
Table 2. Overall, there were more boys than girls (63.3%
vs 36.7%, respectively). The average age at treatment start
was 9.7 years and average treatment duration 3.5 years.
The intermediate-risk group was the only group with a
majority of girls (51.5%). However, without patients with
Turner syndrome (n = 2402; 23.2% of the intermediaterisk group), the sex ratio in the intermediate-risk group was
63.1% boys and 36.9% girls. Patients in the intermediaterisk group were on average younger at the start of treatment
(8.4 years), with a lower baseline height SD score (SDS;
–2.5) and longer duration of GH treatment (4.2 years)
compared with the low- and high-risk groups.
Within the low-risk subgroups, on average, children
born SGA started treatment earlier (age 8.2 years) with a
lower height SDS (–2.7) and were treated for a longer period
(3.7 years) than the non-SGA patients (age 10.6 years,
height SDS –2.2 and treatment duration 3.0 years).

1732

2.3 (2.2)
2.6 (2.5)

588 (52-2066)
541 (59-2009)

dose up to the first AE as a continuous variable, a significant inverse relationship with GH dose was shown for
incidence rates of ADRs and SAEs in the low-risk group
(P = .003 and P = .001, respectively) and for SAEs in the
intermediate- and high-risk group (P = .002 and P = .048,
respectively) (Fig. 2B). Within the low-risk group, an inverse
relationship with GH dose was found for incidence rates of
ADRs and SAEs in the non-SGA subgroup (both P = .002)
(Fig. 3B).
Analysis of the annual incidence of AEs has shown that
the proportion of patients experiencing ADRs, SAEs, and
SADRs among all exposed patients remained relatively
stable throughout 5 years of follow-up (0.3%-0.6% for
ADRs, 0.2%-0.3% for SAEs, and 0.0%-0.1% for SADRs;
Fig. 4). There was a significant negative correlation between
the occurrence of ADRs and the duration of GH treatment
(P = .037), whereas it was not significant for SAEs and
SADRs (P = .624 and P = .188, respectively).

Safety Profile

Data are reported as mean (SD) unless otherwise specified.
Abbreviations: AE, adverse event; GH, growth hormone; SGA, small for gestational age.
a
Data are reported as median (10th-90th percentile).

288 (1.4)
93 (1.7)
20 448
5342

38.4 (11.0)
39.9 (11.1)

38.5 (11.9)
39.0 (11.4)

543 (64-2139)
2.5 (2.2)
107 (6.9)
1543

31.0 (10.8)

30.8 (11.2)

579 (56-2043)
584 (52-2189)
2.4 (2.3)
2.9 (2.8)
38.6 (11.8)
36.2 (12.9)
381 (1.5)
361 (3.5)

Low risk
Intermediate
risk
High risk
Low-risk subgroups
Non-SGA
SGA

25 790
10 369

38.7 (11.0)
36.6 (12.4)

Duration of GH treatment up to first AE, y
Average GH dose prior
to first AE, μg/kg/d
Patients with AE,
n (% of group)
Patients in
group, n
Risk group

Table 3. Growth hormone dose up to first adverse event

1733

Adverse events by system organ class and preferred term
ADRs were most frequent among “nervous system disorders” (236 events), “musculoskeletal and connective
tissue disorders” (228 events), and “general disorders and
administration-site conditions” (104 events) (Fig. 5). The
most common preferred-term ADRs were headache (205
events), arthralgia (92 events), scoliosis (42 events), and
injection-site reaction (26 events).
SAEs were most frequent in “nervous system disorders”
(123 events), “musculoskeletal and connective tissue disorders” (70 events), and “infections and infestations” (68
events) (see Fig. 5). The most common preferred-term
SAEs were seizure (44 events), and SCFE and scoliosis
(20 events each). Of the total 656 SAEs, 15 had a fatal
outcome, details of which have been described previously
(17). Among the low-risk subgroups, children born SGA
were more likely to experience SAEs (1.0% of patients in
the subgroup) than non-SGA children (0.2% of patients
in the subgroup). This difference was most pronounced in
“respiratory, thoracic, and mediastinal disorders” (7.7%
vs 0.8% of events in SGA and non-SGA groups, respectively) and “skin and subcutaneous tissue disorders” (7.7%
vs 1.6% of events). In non-SGA children, SAEs were more
often reported in “psychiatric disorders” (9.0% vs 0.0%
of events in non-SGA and SGA groups, respectively) and
“musculoskeletal and connective tissue disorders” (17.2%
vs 4.6% of events).
SADRs were overall most frequent in “musculoskeletal and connective tissue disorders” (47 events) and “nervous system disorders” (36 events) (see Fig. 5). The most

Downloaded from https://academic.oup.com/jcem/article/106/6/1728/6133442 by Thomas Jefferson University user on 27 June 2021

GH dose at onset
of AE, μg/kg/d

Cumulative absolute
dose up to first AE, mga
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Table 4. Number of patients and patient-years in growth hormone dose groups within each risk group and low-risk
subgroups
Risk group
Low risk

Intermediate risk

Low-risk subgroups
Non-SGA

SGA

Patients, n (% of risk group)

Patient-years

0-30
30-40
> 40
0-30
30-40
> 40
0-30
30-40
> 40

3617 (14.2)
8000 (31.5)
13 793 (54.3)
2773 (27.1)
3167 (31.0)
4280 (41.9)
650 (42.8)
435 (28.6)
434 (28.6)

13 571
28 799
38 240
13 187
13 708
16 140
2811
1658
1231

0-30
30-40
> 40
0-30
30-40
> 40

2983 (14.8)
5597 (27.8)
11 553 (57.4)
634 (12.0)
2403 (45.5)
2240 (42.4)

11 391
19 266
30 424
2179
9533
7815

Abbreviations: GH, growth hormone; SGA, small for gestational age.

common preferred-term SADRs were SCFE (18 events),
headache, and increased ICP (12 events each).
Vascular events in the low-risk group
There were 2 cardiovascular events in 2 individual patients,
both of whom made a recovery. One non-SGA patient experienced hypotension, an SAE considered possibly related
to GH treatment. It occurred after 3.5 years of GH treatment with an average dose of 41.5 µg/kg/day. One SGA
patient reported a hematoma on the left thigh (not serious
and possibly GH-related) after 8.1 years of GH treatment
with an average dose of 35.8 µg/kg/day. There were no
cases of cerebral hemorrhage in any risk group.
Neoplasms
At baseline, 281 patients (2.7%) in the intermediate-risk
group and 868 patients (56.3%) in the high-risk group had
a medical history of a neoplasm before GH treatment initiation. Over the course of the study, 56 patients reported 62
neoplasms, of which 37 (59.7%) were considered unlikely
related to GH treatment, 22 (35.5%) were possibly GH related, and 3 (4.8%) were probably GH related. Details about
the diagnoses and GH treatment of these 56 patients are
summarized in Table S1 in the Supplementary Material (23).
Eight neoplasms in 8 patients (0.03%) were reported
in the low-risk group. Two of them (0.04%) occurred in
the SGA subgroup (benign oral neoplasm possibly GH related, and T-cell lymphoma unlikely GH related), and 6
(0.03%) in the non-SGA subgroup (nephroblastoma and
Langerhans cell histiocytosis unlikely to be GH related,

benign juvenile melanoma and malignant mixed mesenchymal tumor possibly GH related, and melanocytic nevus
and lipoma probably GH related). None of these patients
had a prior history of a neoplasm.
In the intermediate-risk group, 22 neoplasms were reported in 21 patients (0.20%), of which 14 were unlikely
to be related to GH treatment, 7 possibly, and 1 probably
GH related. Six of these patients had history of a neoplasm
before starting GH treatment.
There were 32 neoplasms in 27 patients (1.75%) in the
high-risk group, of which 20 were considered unlikely to
be related to GH treatment and 12 possibly related. Of the
27 patients, 25 had a history of a malignancy prior to GH
treatment initiation. Four events had a fatal outcome (recurrent medulloblastoma unlikely to be related, primitive
neuroectodermal tumor unlikely to be related, metastases
to meninges possibly related, and acute myeloid leukemia
unlikely to be related to the GH treatment). A single case
of bone cancer (osteosarcoma in the occipital region) occurred in a 10-year-old girl after 5 years of GH treatment
indicated for GHD, with an average dose of 38.6 µg/kg/
day. The patient had a history of medulloblastoma diagnosed before the start of GH treatment. After the diagnosis
of osteosarcoma, GH treatment was discontinued and the
event was considered unlikely related to the treatment.
Targeted adverse events
There were 18 events both of edema and increased ICP, 21
events of SCFE, and 207 events of headache. Edema was the
most common in the intermediate-risk group (12/18 events;
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2.1% of all AEs in the risk group), whereas headache and
increased ICP were the most common in the low-risk group
(106/207 [21.3%] and 10/18 [2.0%], respectively). SCFE
occurrence was the highest in the high-risk group (4/21
events; 2.4% of all AEs in the group). Among the low-risk
subgroups, the occurrence of edema and increased ICP was
higher in the non-SGA children compared with those SGA

Discussion

Figure 1. Comparison of average growth hormone dose between patients who did or did not experience at least one adverse event in A, risk
groups and B, low-risk subgroups. Only significant P values (< .05) are
shown. For patients with AEs, average GH dose up to the first AE onset
was used. For patients without AEs, average GH dose from the full treatment period was used. AE, adverse event; GH, growth hormone; SGA,
small for gestational age.

This analysis of 2 large, noninterventional, real-world
studies, the NordiNet IOS and ANSWER Program, provides valuable insight into the safety of GH treatment with
5-year follow-up in clinical practice. No unexpected safety
signals were observed, and the safety profile of GH treatment in this analysis was consistent with other observational studies reported previously (8, 24-26), including our
preliminary analysis of data from the NordiNet IOS (16).
Analyses presented in this report were based on patients
categorized into 3 risk groups to overcome the complication of analyzing a highly heterogeneous cohort with different preexisting risks. Indeed, we observed that the AE
incidence rates within the study period correlated with
increasing risk category for all 3 types of AE (Fig. 2A), as
was the proportion of patients experiencing any AEs (see
Table 3). However, the frequency of ADRs showed the opposite trend, as the proportion of ADRs declined with increased risk category (see Table 5). These observations are
likely related to the inherent increased risk and seriousness of events associated with the underlying diagnoses of

Table 5. Frequency of adverse drug reactions, serious adverse events, and serious adverse drug reactions by risk group
Risk group
Low risk
Intermediate risk
High risk
Low-risk subgroups
Non-SGA
SGA

Patients in group (n)

Patient-years

ADRs, n (%)

SAEs, n (%)

SADRs, n (%)

25 790
10 369
1543

81 332
43 385
5759

383 (76.9)
311 (54.3)
80 (47.3)

187 (37.6)
351 (61.3)
118 (69.8)

72 (14.5)
89 (15.5)
29 (17.2)

20 448
5342

61 693
19 639

307 (81.4)
76 (62.8)

122 (32.4)
65 (53.7)

52 (13.8)
20 (16.5)

Abbreviations: ADR, adverse drug reaction; SADR, serious adverse drug reaction; SAE, serious adverse event; SGA, small for gestational age.
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(5/5 and 8/10 events, respectively [1.3% and 2.1% of all
AEs in the subgroup, respectively]). Headache occurred at
a similar rate in both subgroups (81/207 [21.5%] in the
non-SGA and 25/207 [20.7%] in the SGA subgroup), as
well as SCFE (6/8 [1.6%] in the non-SGA and 2/8 [1.7%]
in the SGA subgroup).
Patients experiencing any of the 4 targeted AEs received
a higher mean GH dose at the AE onset (38.9-43.7 µg/kg/
day) compared with the whole patient population (30.838.6 µg/kg/day). The average duration of GH treatment up
to the AE onset was shorter in patients experiencing increased ICP and edema (1.5 and 1.8 years, respectively)
and similar for SCFE and headache (2.7 and 2.4 years, respectively), compared with the whole population for any
AE (2.4-2.9 years). Diagnoses of the patients experiencing
these targeted events, together with information about the
duration of GH treatment and GH dose, are summarized in
Table S2 in the Supplementary Material (23).
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patients in the high-risk group (eg, chronic kidney disease
and malignant tumors prior to GH treatment).
There was no evidence indicating an increased risk of
experiencing AEs with increased GH dose. On the contrary,
patients who experienced 1 or more AEs received a lower
average GH dose up to the time of the AE onset, compared
with the average dose for patients without any AEs. This
result was consistent across risk groups and statistically significant in the low- and intermediate-risk groups and in the
non-SGA low-risk subgroup (see Fig. 1). Similarly, we observed a significant decrease in incidence rates of ADRs and
SAEs with the increasing average GH dose in the low-risk
group (overall, and specifically in the non-SGA subgroup),
and also in incidence rates of SAEs in the intermediate-and
high-risk group. For the remaining groups and event types,
the incidence of AEs appeared independent of the GH dose
(see Fig. 2B).
The inverse relationship between AE incidence rates
and GH dose may be partially explained by the practice of
prescribing lower GH doses to patients who were overall
more likely to experience AEs. This notion is supported
by the decreasing mean GH dose at AE onset with the
increasing risk category (38.4, 35.9, and 30.9 μg/kg/day
in the low-, intermediate-, and high-risk groups, respectively). The relationship may also be partially driven by the

higher likelihood of experiencing some treatment-related
AEs (eg, edema or increased ICP [8, 27]) in the early stage
of GH treatment, while receiving a lower starting GH dose.
Indeed, the proportion of patients experiencing ADRs was
slightly elevated during the first year of GH treatment (see
Fig. 4).
Within the low-risk group, incidence rates were significantly lower for ADRs, but significantly higher for SAEs in
the SGA subgroup compared with the non-SGA subgroup.
A similar pattern was observed in the previous analysis
from NordiNet IOS (16). The frequency of SAEs among all
AEs was 1.7-fold higher for SGA children compared with
non-SGA children (see Table 5). However, the average GH
dose prior to AE onset between these 2 groups was similar,
despite a higher recommended dose for SGA (35 µg/kg/day
in Europe and ≤ 67 µg/kg/day in the United States) compared with the GHD indication (25-35 µg/kg/day in Europe
and 24-34 µg/kg/day in the United States). The higher incidence of SAEs in children born SGA may be related to
their intrinsic higher morbidity profile compared with peers
born appropriate for gestational age (28, 29).
The mean duration of GH treatment up to the onset
of the first AE was quite long (2.3-2.9 years across risk
groups). The duration of GH treatment up to the first AE,
as well as the overall duration of GH treatment, was the
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Figure 2. A, Incidence rates (events/1000 patient-years of exposure within the study period) for reported adverse drug reactions (ADRs), serious adverse events (SAEs), and serious adverse drug reactions (SADRs) by risk groups. B, Incidence rates for ADRs, SAEs, and SADRs by average growth
hormone dose up to the first AE within each risk group. Only significant P values (< .05) are shown.
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Figure 4. Proportion of patients with at least one adverse drug reaction (ADR), serious adverse event (SAE), or serious adverse drug reaction (SADR)
of all patients exposed in a given year by duration of follow-up. GH, growth hormone.

longest in the intermediate-risk group. This could be partially explained by the relatively high proportion of patients with congenital conditions (eg, Turner syndrome),
many of whom are diagnosed early in life. The proportion
of patients experiencing AEs by year of follow-up remained
quite stable throughout 5 years. This indicates that the

likelihood of experiencing AEs was low and relatively consistent throughout the duration of GH treatment.
Of the 62 neoplasms reported in this study, most (52%)
were reported in the high-risk group. This was expected, as
patients with an underlying history or risk for malignancy
were included in the high-risk group, and the majority of
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Figure 3. A, Incidence rates (events/1000 patient-years of exposure within the study period) for reported adverse drug reactions (ADRs), serious adverse events (SAEs), and serious adverse drug reactions (SADRs) in the low-risk group by subgroup (non–small for gestational age [SGA] vs SGA). B,
Incidence rates for ADRs, SAEs, and SADRs by growth hormone dose up to the first AE in each subgroup. Only significant P values (< .05) are shown.
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the patients in this group (93%) had a previous medical
history of a neoplasm before the start of GH treatment.
There was a single case of osteosarcoma throughout the
duration of the 2 studies, and it occurred in the high-risk
group. This is in contrast with the French SAGhE study, in
which 5 of 6874 low-risk patients experienced bone or cartilage tumors (13). Additionally, there were no cases of cerebral hemorrhage in the low-risk group in our study, which
contrasts with the 7-fold increased mortality ratio due to
cerebrovascular diseases in the French SAGhE cohort (12).
However, as was later shown for the full SAGhE population, the elevated mortality risk in the low-risk patients was
driven mainly by the French SGA subcohort (15). In addition, our data report events occurring during GH treatment, whereas SAGhE analyzed events occurring in older
individuals who received GH treatment as children.
The lack of follow-up beyond the cutoff age of 20 years
likely limits the potential of our data to capture the risk of
developing noncommunicable diseases (eg, diabetes, cardiovascular morbidity, or neurodegenerative diseases) in older
age. The etiology of such diseases can originate as early as
during intrauterine development and early childhood, and
is thus influenced by factors beyond genetic predisposition,
for example, environmental factors (30, 31). In a recent

analysis of long-term risk of cardiovascular morbidity in
Swedish patients treated with GH in childhood, the authors
have partially accounted for this phenomenon (32). In addition to a long follow-up period of up to 25 years, each
patient was matched with 15 control individuals from the
general population matched for sex, birth year, and geographical region, and important covariates were included,
such as birth characteristics and socioeconomic status (32).
Capturing such a breadth of information is useful for retrospective analyses of long-term safety, as the baseline risk for
noncommunicable diseases changes over time (33).
Among the 4 targeted AEs (SCFE, headache, increased
ICP, and edema), only SCFE was the most common in the
high-risk group. Notably, of the 21 cases of SCFE, 5 occurred in conditions with previously reported increased
risk of SCFE (Turner syndrome, chronic renal insufficiency, and inflammatory bowel disease with presumed
glucocorticoid treatment) (34-36). Patients experiencing
SCFE also received a higher average GH dose up to the
AE onset (43.7 µg/kg/day) compared with the whole patient population (30.9-38.6 µg/kg/day), which may have
contributed to the rapid height velocity associated with
SCFE (34), or to acute joint changes. Edema and increased ICP are likely related to the water retention and
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Figure 5. Frequency of adverse drug reactions (ADRs), serious adverse events (SAEs), and serious adverse drug reactions (SADRs) across all risk
groups by system organ class (SOC). Only SOCs with more than 10 events are shown. *Including cysts and polyps.
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of AEs could be diluted. However, we have addressed this
potential concern by categorizing the patients into relevant
risk groups and subgroups.
In summary, we found no indication of increased risk
of mortality or incidence of AEs related to GH dose in any
risk group. Our findings support a favorable benefit-risk
profile of GH treatment across the indications included in
the NordiNet IOS and the ANSWER Program.
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temporary imbalance of cerebrospinal fluid production
and resorption associated with GH treatment (20, 37),
and thus possibly related to GH dose. Patients experiencing edema or ICP increase received a higher average
GH dose (39.0-39.8 µg/kg/day) than the whole patient
population, although this difference was less pronounced
than in the patients with SCFE. It is possible that patients experiencing these targeted events had a relatively
high sensitivity to GH. Given the possible link between
the targeted events and GH dose, a gradual GH dose increase could be considered for future studies. Lastly, the
patients who reported headache received similar average
GH dose as patients in the low-risk group, which is where
it was most frequently reported. Formulating hypotheses
about the relationship between GH treatment and headache is limited by the low specificity of the symptom and
the heterogeneity of concomitant diagnoses (Table S2 in
the Supplementary Material [23]).
The strengths of our study lie in the pooling of data
from 2 large observational studies with a similar design,
which provide a greater number of cases for investigation of patient subgroups and infrequent events, as well as
strengthening the statistical power of the data. The confidence in our findings is further underpinned by the methodical validation of data entry (18), systematic checking
for outliers, and elimination of obvious data entry errors.
The NordiNet IOS and the ANSWER Program were not
constrained by a highly specific protocol, and offer an inclusive picture of the use and effectiveness of GH treatment
in clinical practice.
Limitations of our study include the lack of an untreated
control group, which limits the impact of drawing conclusions from the results. However, this is an inherent limitation of all noninterventional observational studies, and
conducting a long-term randomized trial would be unfeasible and unethical. Given the multinational nature of our
study, there is a potential for confounding of the results by
local differences in diagnostics, laboratory analyses, and reporting of events among different clinics and countries, resulting in a potential lack of firm diagnoses in some patients.
However, an earlier analysis of between-country reporting
rates for AEs in the NordiNet IOS revealed no obvious differences (16). Limitations in the study design include data
on AE-related discontinuations not systematically collected
in either registry, and voluntary ascertainment that could
introduce a bias and/or lead to incomplete data capture.
Lastly, the patient cohort in the ANSWER Program had a
large number of children with idiopathic short stature and
isolated GHD. Because these groups have previously been
shown to have fewer side effects (15), and the ANSWER
Program cohort received higher GH doses in general (17),
the relationship of higher doses to an increased incidence
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